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general rule is the cardiovascular component, which uses vaso-
pressor doses, because it is impossible to avoid a treatment-
related variable for this system. The SOFA score includes the 
assumed Glasgow Coma Scale (GCS) score, that is, the GCS 
that the patient would have in the absence of any sedation, to 
evaluate neurologic function. If the GCS is assessed as is, with-
out taking into account the effect of sedation, its prognostic 
value will be skewed. If the GCS score is not mentioned, one 
should consider that it is 15 of 15.
The RASS not only is a marker of brain dysfunction/dam-
age but can also be just a measure of the degree of sedation. 
Although the score proposed by Vasilevskis et al may provide 
similar prognostic information to the GCS, it will vary consid-
erably depending on the sedation practices used in different 
ICUs. As an example, a GCS score of 3–5 as a result of organic 
brain injury will certainly have a different prognostic implica-
tion than a similar GCS score in a patient receiving deep seda-
tion for agitated delirium.
We acknowledge that people may not always collect the 
data for the SOFA correctly, but this is not a reason to discard 
the system. As an analogy, none would suggest discarding the 
electrocardiogram just because some people cannot read or 
interpret it! It is obvious that the RASS has prognostic value, 
as does the use of sedative agents or mechanical ventilation; 
this is not at all surprising. However, using the RASS to replace 
the GCS in the evaluation of neurologic status does not make 
much sense.
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The Richmond Agitation-Sedation Scale 
Should Not Be Used to Evaluate Neurologic 
Function
To the Editor:
We were quite astonished to read the article by Vasi-levskis et al (1) published in a recent issue of Criti-cal Care Medicine. To us, there is no point in using 
the Richmond Agitation-Sedation Scale (RASS) to evaluate 
neurologic dysfunction when this scale was developed to adapt 
sedative therapy (2) and is, therefore, therapy dependent. By 
contrast, the aim of the Sequential Organ Failure Assessment 
(SOFA) score (3) is to evaluate the degree of organ dysfunction 
by using a system that minimizes as much as possible the effect 
of therapeutic interventions; the notable exception to this 
et al (1) commented specifically on three cases of pulmonary 
embolism following 31F bicaval dual-lumen (Avalon ELITE; 
Maquet, Rastatt, Germany) catheter removal which they had 
seen. In our case series, there were not any clinically demon-
strated pulmonary embolism following cannula removal, either 
with dual lumen bicaval cannulae or single lumen cannulae.
We agree that the prevalence of DVT following ECMO is 
of great concern, particularly following cannulation of the 
upper extremities. The risks and the therapeutic implications 
of DVT of the upper extremities are increasingly recognized 
(3). Given our experiences and those of others, including 
Staudacher et al (1), we think that the prevalence of upper 
extremity DVT following bicaval dual lumen cannulation is 
likely to contribute to significant morbidity. We would rec-
ommend that manufacturers, regulators, or bodies such as 
the Extracorporeal Life Support Organisation form a pro-
spective registry to better understand the true prevalence and 
consequences of thromboembolic disease following ECMO 
cannulation.
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